We have analyzed the putative value of the pattern of relative expression (RE) of several genes that might be involved in a response to anti-cancer therapy, namely AR, PTEN, COX2, FASN, HMGCR, LDLR, and CTLA4, in 
An analysis of the gene expression pattern, assessed by a quantitative PCR method, is a powerful approach to solve important questions of modern molecular biology and medicine. Earlier, we used such analysis for the profiling of prostate cancers and creation of a diagnostic panel [1] [2] [3] [4] . Next, we wanted to explore the possibility to use the gene expression analysis to predict the efficacy of anti-cancer therapy and to evaluate components of a tumor microenvironment. Both questions are crucial for personalized medical treatment.
It is widely accepted now that one of the most important prediction tools to choose the correct patient treatment is the sensitivity of tumor cells to inhibitors of androgen receptor (AR). These drugs are used at the first line of prostate cancer treatment [5] . Hence, high expression of AR is favorable for effective therapy. Of note, low expression of a tumor suppressor PTEN or its mutations in prostate tumors results in a better response to inhibitors of the PI3K/AKT/mTOR signaling pathway. Importantly, PTEN itself is the inhibitor of this pathway [6] . That's why the Results and Discussion. RE levels of seven genes often targeted by inhibitory drugs were assessed in PAC, CNT, and AD groups [1, 14] . Surprisingly, no significant differences in RE of these genes were found between groups of PAC and CNT. Instead, differences in RE between PAC and AD as a control were calculated ( Table 1 ). The analysis of RE levels in PAC and AD groups showed three types of changes: (1) significantly decreased expression in PAC -AR 1 isof, PTEN); (2) significant ly increased expression in AD -COX2, FASN, CTLA4; (3) no significant changes in RE -HMGCR, LDLR. Of note, all genes showed variable expression in individual tumors.
We ranged the putative efficacy (or sensitivity) to anti-cancer therapy as high, middle, lower middle, and low.
RE in AD was used as a control. Therefore, the first threshold level was a median for genes with RE changes of type (1) . It could be divided into high and middle ranges. The next threshold level was a 25-th percentile of the AD group. It was divided in middle and lower middle ranges. These values are close to the median of the PAC group. The last threshold level was a 25-th percentile of the PAC group; it was divided in lower middle and low ranges. For the type (2) of RE changes, we proposed an extra range, i.e. a very high level of sensitivity/efficacy. Its threshold level is the median of PAC.
The type (3) of RE changes allow us to range efficacy similarly to type (1), except an additional very high level, if RE of a 75-th percentile of PAC was higher than in AD.
The summarized results of ranging for seven genes are shown on Fig. 1 .
It is important to note that the threshold levels of AR 1 isoform are very similar to levels of RE means for three subtypes of PAC characterized earlier [1] . Moreover, RE levels of PTEN inversely related to pharmacological efficacy of mTOR inhibitors.
The obtained results are our assumptions based on the RE and characteristics of RE changes in groups of prostate tumors. In order to establish the real sensitivity and efficacy for anti-cancer therapy, the clinical studies should be performed. On the other hand, these results suggest the different putative sensitivity to anti-cancer therapy.
As discussed above, the tumor microenvironment plays an important role in the control over the efficacy of anti-cancer therapy. Many components such as CAFs, TAMs, and tumor-infiltrating lymphocytes (TIMs) are known to orchestrate and support the development and expansion of tumors and reduce the effectiveness of antitumor therapy [6, 7] . To define the specific stromal subtypes in prostate cancer, RE of genes characteristic of CAFs (8 genes) (Fig. 2, a) , TAMs (6 genes) (b), and immune-associated genes (IAGs) (9 genes) (c) was treated by the Kmeans clustering. All studied genes were clustered in three PAC groups based on various patterns of RE changes. The first and second clusters contain predominantly tumors at the Stage 1-2, whereas the third cluster consists of the advanced prostate tumors (Stage 3-4 ). The CAF group shows differences in RE between three clusters for 7 out of 8 genes, i.e. except CXCL14. Nevertheless, the CXCL14 gene has a tendency to changes in RE. In the TAM group, all 6 genes are expressed differently. The smallest number of genes with RE changes between clusters was calculated for the IAG group: only CTLA4, IRF1, IL2RA, and HLA-G demonstrated the altered expression pattern. Based on the obtained data, we performed clustering for the CAF, Tam, and IAG groups for all the genes that showed differences in RE (Fig. 3) . We could form also three clusters for PAC. Clusters 1 and 2 consist of samples at Stage 1-2, as was described earlier by us. Cluster 3 contains mainly PAC at Stage 3-4. Of note, differences in RE between clusters vanished for the majority of CAF genes, except for CXCL12 and HIF1A.
Based on these results, we performed a correlation analysis between clusters of different types and between clusters of PAC. To do so, we took into account RE of 33 transcripts from genes associated with EMT and prostate cancer-associated genes (T) determined earlier [3] . The Spearman rank order correlations analysis for all cluster types was performed (Table 2) .
One group of clusters (T) contains genes associated with tumor cells, and other three cluster types contain markers of stromal elements described above. All cluster types with stromal elements have high correlations between each other, indicating a significant relationship of CAFs, TAMs, and immune cells upon prostate carcinogenesis.
The most interesting is a high degree of correlation of clusters of microenvironment components with tumor cells. The highest levels of correlation showed the T and CAF groups. Obviously, upon prostate tumor development, there is the strong interaction between the tumor cells and stromal fibroblasts.
Cluster 1 of PACs consists of TMPRSS2-ERG positive androgen-sensitive tumors of the luminal subtype 1. These tumors, in addition to the high sensitivity to androgens, show the high sensitivity to prolactin, insulin growth factor 1, insulin stimulating oncogenic signals and have the activated oncogenic pathways, involving ERG and PCA3. The CAF cluster 1 corresponding to this PAC cluster is characterized by the lowest levels of RE of CAF markers, indicating a small Fig. 3 . Profiling of RE in PAC of 18 genes from the CAF, TAM, and IAG groups (total TM group), using the K-means clustering number of these cellular elements and their low activity, suggesting a favorable prognosis of the disease.
For cluster 2 of tumor markers and characteristics of CAF, tumors are of the same stage, as in cluster 1. However, several epithelial and luminal markers (KRT18, PCA3, PSA) showed the lowest expression, while mesenchymal markers (CDH2, MMP2, FN1, VIM) were highly expressed. This corresponds to a stem-cell-like (basal) subtype of prostate cancer [3] . Simultaneously highly expressed ESR1, SRD5A2, INSRB, PRLR, and lncRNA HOTAIR suggest that this cluster includes tumors with enhanced carcinogenic properties. The CAF cluster 2 includes samples with the highest RE of six genes (ACTA2, CXCL12, CTGH, THY1, HIF1A, FAP) associated with a poor prognosis of a course of disease.
Cluster 3 contains advanced tumors at Stage 3-4. Mainly tumors are androgen independent and castrate-resistant of luminal subtype. The CAF characteristics are between clusters 1 and 2. However, samples in this cluster show very high level of RE of the TAM marker CD163, which is usually expressed in M2 macrophages. Obviously, tumor supportive macrophages contribute to progression of cancer disease [15] .
We could distinct two molecular subtypes of PACs of the luminal type (clusters 1 and 3) with specific tumor gene expression characteristics at early and advanced stages. To these two PAC subtypes, two different CAF subtypes with high and low expression of CAF markers correspond. Similar trend was observed for the TAM, IAG, and total stromal clusters. Cluster 2 characterizes early prostate cancers with increased RE levels of basal and tumor stem cells markers in T cluster and specific RE levels of CAF, TAM, IAG genes. Thus, we have found three additional adenocarcinoma subtypes of stromal elements, which matched with three prostate cancer subtypes described by us earlier. These data are very important for better diagnosis and stratification of prostate tumors for the selection of personal treatments.
To summarize the obtained data, we have analyzed the putative value of the pattern of relative expression (RE) of several genes that might be involved in a response to anti-cancer therapy, namely AR, PTEN, COX2, FASN, HMGCR, LDLR, and CTLA4. We could propose three subtypes of adenocarcinomas that show the distinct pattern of expression of the above-mentioned genes characteristic of (1) CAFs, (2) TAMs, and (3) markers of immune response. These groups correlate with the prostate cancer subtypes that were determined earlier, based on the analysis of RE of the epithelial-to-mesenchymal cell transition (EMT) genes and prostate cancer-associated genes. Noteworthy, the highest correlation was found for genes characteristic of CAFs. This emphasizes the importance of the simultaneous analysis of genes involved in various intercellular interactions between tumor cells and cells of tumor microenvironment in prediction of efficacy of anti-cancer therapy. To confirm the presented data, the additional studies on a larger cohort of the prostate cancer patients are required. Note. Italic -p < 0.001; bold -p < 0.0001.
